 | |
| Clinical data | |
|---|---|
| Other names | BIA 5-453; BIA-5-453 |
| Drug class | Dopamine β-hydroxylase inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H15F2N3OS |
| Molar mass | 311.35 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Etamicastat (INNTooltip International Nonproprietary Name; developmental code nameBIA 5-453) is aperipherally selectivedopamine β-hydroxylase (DBH)inhibitor which was under development for the treatment ofhypertension (high blood pressure) andheart failure but was never marketed.[1][2] The peripheral selectivity of etamicastat is in contrast to the earlier DBH inhibitornepicastat, which iscentrally active and produced associatedside effects.[2] Etamicastat was found to reduceblood pressure but not affectheart rate inclinical trials.[2] The development of etamicastat was discontinued by August 2016.[1]
 | Thisantihypertensive-related article is astub. You can help Wikipedia byexpanding it. |
